Chlamydia trachomatis in the United Kingdom: a systematic review and analysis of prevalence studies
- PMID: 15459402
- PMCID: PMC1744901
- DOI: 10.1136/sti.2003.005454
Chlamydia trachomatis in the United Kingdom: a systematic review and analysis of prevalence studies
Abstract
Objectives: To undertake a systematic review to obtain estimates of genital Chlamydia trachomatis prevalence in various populations in the United Kingdom and Ireland; to determine which populations have the highest rates of infection; and to explore the most important determinants of infection.
Methods: Electronic databases were searched using the keywords "chlamydia" and "England," "Wales," "UK," "Scotland," "Ireland," or "Britain." Additional unpublished data and references were solicited from experts. Studies were included in the analysis if C trachomatis prevalence was reported, and if they met inclusion criteria. Nine variables identified as potentially important descriptors of chlamydia prevalence were extracted from each study and analysed using various logistic regression models. Only studies reporting prevalence in female populations were included in the models, because there were few data from males.
Results: 357 studies were identified using the search methods, 90 of which met inclusion criteria, and 19 of which contributed to the final model. The most influential variables on prevalence were age and setting of the population tested. In general practice surgeries, the under 20 year old age group had an estimated prevalence of 8.1% (95% CI 6.5 to 9.9), 20-24 year olds 5.2% (95% CI 4.3 to 6.3), 25-29 year olds 2.6% (95% CI 2.0 to 3.3), decreasing to 1.4% (95% CI 1.0 to 1.9) in those aged over 30 years. Overall, healthcare settings had higher prevalence estimates than population based studies. For example, among under 20 year olds, estimates were 17.3% (95% CI 13.6 to 21.8) in genitourinary medicine clinics, 12.6% (95% CI 6.4 to 23.2) in antenatal clinics, 12.3% (95% CI 9.8 to 15.3) in termination of pregnancy clinics, 10.7% (95% CI 8.3 to 13.8) in youth clinics, 10.0% (95% CI 8.7 to 11.5) in family planning clinics, and 8.1% (95% CI 6.5 to 9.9) in general practice, compared to 5.0% (95% CI 3.2 to 7.6) in population based studies. The type of test, specimen used, date, and location of test were not strongly associated with chlamydia prevalence.
Conclusion: The chlamydia prevalence estimates by age and setting from the model may be used to inform chlamydia screening strategies. The systematic review revealed much heterogeneity in the studies identified, but with clear patterns of prevalence. It also indicated gaps in the knowledge about chlamydia prevalence in certain subgroups such as men and the general population.
Comment in
-
National chlamydia screening programme in England: making progress.Sex Transm Infect. 2004 Oct;80(5):331-3. doi: 10.1136/sti.2004.009787. Sex Transm Infect. 2004. PMID: 15459397 Free PMC article. No abstract available.
Similar articles
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320. Health Technol Assess. 2001. PMID: 12065068
-
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3. Cochrane Database Syst Rev. 2022. PMID: 35593186 Free PMC article.
-
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340. Health Technol Assess. 2006. PMID: 16959170
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280. Health Technol Assess. 2001. PMID: 11701100
-
Antibody tests for identification of current and past infection with SARS-CoV-2.Cochrane Database Syst Rev. 2022 Nov 17;11(11):CD013652. doi: 10.1002/14651858.CD013652.pub2. Cochrane Database Syst Rev. 2022. PMID: 36394900 Free PMC article.
Cited by
-
Frequency of anti-Chlamydia trachomatis antibodies in infertile women referred to Tabriz Al-Zahra hospital.Int J Reprod Biomed. 2017 Jan;15(1):17-20. Int J Reprod Biomed. 2017. PMID: 28280796 Free PMC article.
-
The SPORTSMART study: a pilot randomised controlled trial of sexually transmitted infection screening interventions targeting men in football club settings.Sex Transm Infect. 2015 Mar;91(2):106-10. doi: 10.1136/sextrans-2014-051719. Epub 2014 Dec 15. Sex Transm Infect. 2015. PMID: 25512674 Free PMC article. Clinical Trial.
-
Do sexual health campaigns work? An outcome evaluation of a media campaign to increase chlamydia testing among young people aged 15-24 in England.BMC Public Health. 2013 May 17;13:484. doi: 10.1186/1471-2458-13-484. BMC Public Health. 2013. PMID: 23683345 Free PMC article.
-
Screening for Chlamydia trachomatis in asymptomatic women attending outpatient clinics in a large maternity hospital in Dublin, Ireland.Sex Transm Infect. 2006 Dec;82(6):503-5. doi: 10.1136/sti.2006.020990. Epub 2006 Jul 19. Sex Transm Infect. 2006. PMID: 16854994 Free PMC article.
-
Chlamydia prevalence in the general population: is there a sex difference? a systematic review.BMC Infect Dis. 2013 Nov 11;13:534. doi: 10.1186/1471-2334-13-534. BMC Infect Dis. 2013. PMID: 24215287 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous